[go: up one dir, main page]

UY38717A - Composiciones de liberación extendida biodegradable que contienen acetato de leuprorelina - Google Patents

Composiciones de liberación extendida biodegradable que contienen acetato de leuprorelina

Info

Publication number
UY38717A
UY38717A UY0001038717A UY38717A UY38717A UY 38717 A UY38717 A UY 38717A UY 0001038717 A UY0001038717 A UY 0001038717A UY 38717 A UY38717 A UY 38717A UY 38717 A UY38717 A UY 38717A
Authority
UY
Uruguay
Prior art keywords
compositions containing
extended release
release compositions
leuprorelin acetate
containing leuprorelin
Prior art date
Application number
UY0001038717A
Other languages
English (en)
Inventor
John Middleton
Avinash Nangia
Arthur Mclane John
L Morton Terri
Original Assignee
Tolmar Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar Int Ltd filed Critical Tolmar Int Ltd
Publication of UY38717A publication Critical patent/UY38717A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones y métodos para suprimir la función ovárica en sujetos con cáncer de mama con receptores hormonales positivos.
UY0001038717A 2019-05-27 2020-05-27 Composiciones de liberación extendida biodegradable que contienen acetato de leuprorelina UY38717A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27

Publications (1)

Publication Number Publication Date
UY38717A true UY38717A (es) 2020-11-30

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038717A UY38717A (es) 2019-05-27 2020-05-27 Composiciones de liberación extendida biodegradable que contienen acetato de leuprorelina

Country Status (17)

Country Link
US (1) US20220265760A1 (es)
EP (1) EP3975990A1 (es)
JP (1) JP2022535694A (es)
KR (1) KR20220041782A (es)
CN (1) CN114144169A (es)
AR (1) AR119021A1 (es)
AU (1) AU2020284587A1 (es)
BR (1) BR112021023904A2 (es)
CA (1) CA3141456A1 (es)
EA (1) EA202193257A1 (es)
IL (1) IL288503A (es)
MX (1) MX2021014540A (es)
PH (1) PH12021552976A1 (es)
SG (1) SG11202112888RA (es)
TW (1) TWI757753B (es)
UY (1) UY38717A (es)
WO (1) WO2020240417A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4135830T3 (pl) 2020-12-23 2025-01-07 Tolmar International Limited Układy dla zespołów zaworów strzykawek mieszających i sposoby
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
BR9507313A (pt) 1994-04-08 1997-10-07 Atrix Lab Inc Composição liquida de liberação adequada para a formação de um implante de liberação controlada sistema polimérico curativo filmico microporoso biodegradável precursor de implante de liberação controlada para a implantação em um indivíduo polímero termoplástico solvente orgánico composicão de pré-polimero liquido componente de liberação controlada agente ativo uso da composição liquida de liberação e processos para forma um implante microporoso de liberação prolongada e para liberar um agente ativo em um individuo
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
KR20150017777A (ko) * 2006-01-18 2015-02-17 포시에이서 파마슈티컬스 인코포레이티드 안정성이 강화된 약학 조성물
HRP20231117T3 (hr) * 2007-02-15 2023-12-22 Tolmar International Limited Poli-(laktid-ko-glikolid) sa smanjenim efektom naglog oslobađanja
PL4241849T3 (pl) * 2011-10-14 2025-01-13 F. Hoffmann-La Roche Ag Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2

Also Published As

Publication number Publication date
TWI757753B (zh) 2022-03-11
EP3975990A1 (en) 2022-04-06
US20220265760A1 (en) 2022-08-25
CN114144169A (zh) 2022-03-04
WO2020240417A1 (en) 2020-12-03
TW202110472A (zh) 2021-03-16
AU2020284587A1 (en) 2022-01-06
CA3141456A1 (en) 2020-12-03
IL288503A (en) 2022-01-01
EA202193257A1 (ru) 2022-03-10
KR20220041782A (ko) 2022-04-01
JP2022535694A (ja) 2022-08-10
MX2021014540A (es) 2022-04-12
BR112021023904A2 (pt) 2022-02-01
PH12021552976A1 (en) 2022-07-04
AR119021A1 (es) 2021-11-17
SG11202112888RA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
UY35961A (es) Anticuerpos y fragmentos anti-vista
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2018000454A1 (es) Anticuerpos pd-l1
UY36968A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
CO2019011155A2 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
MX2017014193A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
CL2017002401A1 (es) Anticuerpos contra icos
CL2018002291A1 (es) Anticuerpos anti-fgfr2iiib afucosilados (divisional solicitud 201600221)
CL2015002098A1 (es) “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
WO2016172703A3 (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
DOP2016000163A (es) 5-flúor-4-imino-3-(alquil/alquilo sustituido)-1-(arilsulfonil)-3,4-dihidropirimidin-2(1h)-ona y los procesos para su preparación
TW201613648A (en) Compounds and compositions for immunotherapy
MX2016010080A (es) Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
CR20170111A (es) Derivados de benzodiazepina citotóxicos
BR112016029860A2 (pt) conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos
MX2015012274A (es) Agentes de sub-regulacion del receptor de androgeno y uso de los mismos.
EA202190243A1 (ru) Применение химерных антигенных рецепторов к bcma
UY38717A (es) Composiciones de liberación extendida biodegradable que contienen acetato de leuprorelina
MX2018005070A (es) Composición para el tratamiento de cáncer con expresión del igf-1r.
MX373308B (es) Composiciones que comprenden anticuerpos anti-cd38 y carfilzomib.
EA201791921A1 (ru) Композиции для местного применения, содержащие кортикостероид

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20241206